1. Kamada secures a tender extension for four plasma-derived products. 2. Expected annual sales from this tender are $5-$7 million through Q2-26 to Q1-28. 3. 2025 revenue guidance remains $178-$182 million; EBITDA guidance is $40-$44 million. 4. Kamada projects double-digit growth in revenue and profitability for 2026. 5. CEO emphasizes ongoing commercial potential in international markets.
FAQ
Why Bullish?
The extension of the tender ensures steady revenue flow, similar to past announcements that positively impacted share prices.
How important is it?
The article highlights significant contracts and revenue projections that directly influence KMDA's market performance.
Why Long Term?
The secured contracts and growth projections will affect revenue stability and investor confidence over the next several years.
Related Companies
Kamada Ltd. Secures $10-$14 Million Supply Tender Extension in Canada
REHOVOT, Israel, and HOBOKEN, N.J., December 18, 2025 (GLOBE NEWSWIRE) - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a leading global biopharmaceutical company specializing in plasma-derived products, has announced an extension of its existing supply tender with Canadian Blood Services (CBS). This extension, valued between $10 million to $14 million, ensures continued sales of four specialty plasma-derived products until Q1 2028, reinforcing Kamada’s position in the Canadian market.
Details of the Supply Tender Extension
Kamada's recent award extends the supply of four key products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. This extension, which spans from Q2 2026 to Q1 2028, secures ongoing annual sales of approximately $5 million to $7 million.
These products are already approved by both Health Canada and the U.S. Food and Drug Administration (FDA), allowing Kamada to maintain a steady supply in every province and territory in Canada, except Quebec.
Strategic Growth and Financial Outlook
Amir London, CEO of Kamada, emphasized the significance of this tender extension. "This award extension, together with continued supply of KAMRAB®, validates our position as the leading supplier of specialty plasma-derived products in Canada," he noted. He further expressed confidence in the company's growth potential for AAT (Alpha-1 Antitrypsin) and specialty immunoglobulin products internationally.
Kamada has reaffirmed its full-year revenue guidance for 2025, projecting earnings between $178 million and $182 million and adjusted EBITDA of $40 million to $44 million. The company anticipates double-digit growth in revenues and profitability in 2026, driven by its robust commercial product lineup and ongoing expansion of plasma sales.
About Kamada Ltd.
Kamada Ltd. specializes in biopharmaceutical products for rare and serious conditions. Its strategy is centered on generating profitable growth through:
- Organic Growth: Enhancing its proprietary product lineup, which includes six FDA-approved specialty plasma-derived products.
- Business Development: Actively pursuing collaborations, licensing, and acquisition opportunities to enhance its market presence.
- Plasma Operations Expansion: Increasing plasma collection to support sales and meet rising demand.
The company currently operates three plasma collection centers in Texas. FIMI Opportunity Funds, a leading private equity firm in Israel, holds approximately 38% of Kamada's ordinary shares.
Cautionary Note Regarding Forward-Looking Statements
This announcement contains forward-looking statements as defined in Section 21E of the U.S. Securities Exchange Act of 1934. These statements, which include guidance on financial performance and strategic initiatives, are subject to numerous risks and uncertainties that may cause actual results to differ materially. Factors such as global market conditions, regulatory changes, and operational challenges may influence outcomes.
Contact Information
For further inquiries, please contact:
- Chaime Orlev
Chief Financial Officer
IR@kamada.com - Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com